companies / artbio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-16 json
| total_raised | 243,000,000243.0M | ○ |
|---|---|---|
| founded | 2021 | |
| hq | Cambridge, USA | |
| industry | unknown | |
| stage | series-b+ |
ARTBIO develops alpha radioligand therapies that deliver targeted radiation directly to cancer cells. The therapies are designed for patients with solid tumors including prostate, non-small cell lung, pancreatic, and triple-negative breast cancers. It runs a proprietary Pb-212 isotope production platform spanning drug design, manufacturing.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-07-01 | series-b | 132,000,000132.0M | null | ○ |
Netlify, Gatsby 4.25.9, React, Webpack
| fact | status | src |
|---|---|---|
| Series B, $132.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |